

Eagle Pharmaceuticals (EGRX : US\$33.66)

Eagle Pharmaceuticals soars 90% in 2015, outperforming Medical sector

Eagle Pharmaceuticals Inc, NASDAQ's 26th largest medical company by market cap, has now soared US\$15.95 (or 90.1%) year to date in 2015 to close at US\$33.66. This gain makes the stock the fourth highest rising one in the Medical sector which is up 13.4% in 2015. The volume YTD has been 2.5 times average trading of 96,057 shares. Compared with the NASDAQ-100 Index which has risen 5.5% YTD, this represents a relative price increase of 84.6%. In 2015 the market cap has jumped US\$223.8 million. Revenue surged at a brisk 80.2% year-on-year.

Introduction

We are currently bearish on this stock in the long-term based on fundamental metrics, but are neutral in the short-term based on technical indicators

There are some reasons why we remain neutral on the stock for the short-term:

- Its Moving Average Convergence Divergence indicators are rising, with its 12-day EMA higher than its 26-day EMA.
- The price to 200-day MAP ratio is 1.97, a bullish indicator.

Stock Summary

52-Week Range	US\$9.16-US\$40.90
Sector	Medical
Market Cap	US\$472.3 million
Shares Outstanding	14,032,167
ISIN	US2697961082
Relative Strength (3 mo)	100

Financial Summary

Year ended	Sep 2013	Sep 2012	Sep 2011
Sales (USD)	13.68M	2.54M	9.53M
Pretax (USD)	(6.95M)	(20.16M)	(5.51M)
Net (USD)	(9.89M)	(23.32M)	(8.65M)
EPS (USD)	(0.71)	(1.68)	(0.62)

MCap: A Historical Perspective

	Share Price (USD)	Market Cap (US\$)
Last	33.7	472.3 million
1 Year ago	13.4	185.8 million

Analysis

Bearish Signals

- The price is at a premium of 12.2% to the 1-month volume weighted average price of US\$30.0. Given that this premium has been under 12.2% two hundred fourteen times and over 12.2% thirty-one times in the last year, the downside:upside probability is estimated at 214:31 or 6.9:1.
- The current short volume is 1.6 times its own historical average of 0.1%. It soared 30.6% from the previous day, soared 33.6% from a week ago and soared 81.0% from a month ago, a significant bearish indicator.

Overvaluation:

- Price/Sales of 34.53 versus sector average of 3.0 and market average of 2.4. We estimate the shares are trading at a current year Price/Sales of 22.9 and a forward year Price/Sales of 15.2.

Other Bearish Signals:

The stock has a score of merely 3 out of 9 set by Joseph Piotroski [pass mark ≥ 5]:

Improvement in current ratio from 0.4 to 1.2; Total shares on issue unchanged; improvement in asset turnover [growth in revenue of 438.6% exceeded growth in assets of 91.7%].

Bearish Indicators and Rank in Market:

Description	Value	Rank In Market
Price Change %	-2.8	In Bottom 9%
Annual Revenue	US\$13.7 million	In Bottom 9%

Note

- It is at a discount of 17.7% to the 12-month high of US\$40.90 on 19 Feb, 2015. It is also at a premium of 267.5% to the 12-month low of US\$9.16 on 09 May, 2014.

Beta & Standard Deviation (SD)

The Beta of this stock is 1.6. A Beta greater than 1 suggests this is a high risk, high return stock with volatility greater than that of the market.

SD is a statistical measure of deviation from the mean. The SD of 5.0% gives it a percentile rank of 90 meaning that 90% of stocks in the NASDAQ market are less volatile than this stock.


Neutral Indicators and Rank in Market:

Description	Value	Rank In Market
MCap	US\$472.3 million	In 2nd Quartile
Turnover in Quarter	US\$296.5 million	In 3rd Quartile

Bullish Signals:

- Rises to Falls: In the last three months the number of rises outnumbered falls 32:29 or 1.1:1.
- In the NASDAQ market of 2,407 stocks traded today, the stock has a 6-month relative strength of 99 which means it is beating 99% of the market.
- The Moving Average Convergence Divergence (MACD) indicator of 12-day Exponential Moving Average (EMA) of 30.19 minus the 26-day EMA of 25.44 is positive suggesting a bullish signal. Both the 12-day EMA as well as the 26-day EMA are rising, another bullish signal.
- The Price/MAP of 1.97 for EGRX is higher than the Price/MAP for the NASDAQ-100 Index of 0.3.
- The price to 200-day MAP ratio is 1.97, a bullish indicator. In the past 200 days this ratio has exceeded 1.97, six times suggesting further upside. The stock is trading above both its MAPs and the 50-day MAP of US\$29.71 is higher than the 200-day MAP of US\$17.13, a bullish indicator. The 200-day MAP has increased to US\$17.13. An increase is another bullish indicator.
- The present value of US\$1,000 (PV1000) invested one year ago in Eagle Pharmaceuticals is US\$2,793, for a capital gain of US\$1,793.

PV1000 (1 year)



Analysis (continued)

Other Bullish Signals:


% Growth Y.O.Y, Revenue & Net Profit



Bullish Indicators and Rank in Market:

Description	Value	Rank In Market
Price/MAP200	1.97	In Top 1%
Relative Strength (6M)	99	In Top 1%
Price/MAP50	1.13	In Top 9%
%Prem To Vol Wtd Price	12.2	In Top Quartile
Revenue Per Employee	US\$760,000	In Top Quartile

Relative Strength




Turnover Rate & Turnover Period




Trailing 3 months

Turnover	US\$296.5 million
Volume	10,947,216
Volume Index (1 is avg)	1.9


YTD Comparison Stock Sector Index



Weekly Price Volume Dynamics (Last 12 Weeks)



Stock v Index (Trailing Year)



Price/Moving Average Price [P/MAP]



Recent Analyst Recommendations

Date	Brokerage	Action	Past Rating	Current Rating	Prev Target	Price Target
18-Feb-2015	William Blair	Boost Price Target	-	Outperform	25	43
18-Feb-2015	Cantor Fitzgerald	Reiterated Rating	-	Buy	30	37
22-Jan-2015	Cantor Fitzgerald	Reiterated Rating	-	Buy	-	30
18-Dec-2014	Cantor Fitzgerald	Reiterated Rating	-	Buy	-	30

Company Overview

Activities

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company develops and distributes injectable products, primarily in the critical care and oncology areas. Eagle Pharmaceuticals offers its products to the healthcare and medical industries.

Further details can be found at
www.eagleus.com.

Ranking

Eagle Pharmaceuticals is placed 15/2416 in BSS News Bites's ranking of NASDAQ performers in the past year, a percentile ranking of 99%.

Regulatory Announcements

Financial Results

February 18: Eagle Pharmaceuticals, Inc. Reports Financial Results for Three Month Period Ended December 31, 2014

[News Story] WOODCLIFF LAKE, N.J.-- Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) today announced its financial results for the transitional three-month period ended December 31, 2014 (the "stub period"). This stub period resulted from the previously-announced change in Eagle's year end from September 30 to December 31.

[For more details click here.](#)

Conferences/Exhibitions

February 17: Events Calendar: Eagle Pharmaceuticals to Hold Conference Call at 8: 30 a.m. EST Today to Discuss Licensing Agreement with Teva to Commercialize Eagle's Rapid Infusion Bendamustine

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX), will hold a conference call to discuss its newly-disclosed license agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) for EP-3102, Eagle's bendamustine hydrochloride (HCl) rapid infusion product.

[For more details click here.](#)

January 20: Eagle Pharmaceuticals, Inc. Announces Change in Fiscal Year End

[News Story] WOODCLIFF LAKE, N.J. The Board of Directors of Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) has approved a change in the Company's fiscal year end to December 31. The change will result in a stub period from October 1, 2014 to December 31, 2014, and as a result of the change, the fiscal year 2015 will end on December 31, 2015.

[For more details click here.](#)

Financial Results

December 17 2014: Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Year End 2014 Financial Results

WOODCLIFF LAKE, N.J. Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq: EGRX) today announced its financial results for the three- and twelve- month periods ended September 30, 2014. Highlights of and subsequent to the fourth quarter include:

The U.S. Food and Drug Administration ("FDA") tentatively approved Eagle's bendamustine hydrochloride ("HCl") ready-to-dilute ("RTD") product; Our clinical trial demonstrated that Eagle's bendamustine HCl product administered in a 50mL admixture in 10 minutes ("rapid infusion") is bioequivalent to Treanda(Registered) and has a comparable safety profile; Eagle's bendamustine HCl rapid infusion product was granted orphan drug designation for the treatment of chronic lymphocytic leukemia ("CLL") and indolent B-cell non-Hodgkin's lymphoma ("NHL"), and a new patent covering the product was issued by the U.S.

December 04 2014: Eagle Pharmaceuticals to Discuss 2014 Fourth Quarter and Year-End Financial Results on December 17, 2014

[News Story]

<http://www.nasdaq.com/press-release/eagle-pharmaceuticals-to-discuss-2014-fourth-quarter-and-yearend-financial-results-on-december-17-20141204-01135>

Source: Nasdaq Stock Exchange
[For more details click here.](#)

Conferences/Exhibitions

November 20 2014: Eagle Pharmaceuticals to Present at Piper Jaffray 2014 Healthcare Conference

[Company Release] WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") announced today that Scott Tarriff, President and Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at the Piper Jaffray 26th Annual Healthcare Conference as follows:

Date: Wednesday, December 3, 2014

Time: 2:00 p.m.

Company Overview (continued)

November 11 2014: Eagle Pharmaceuticals Reports Positive Outcomes from Clinical Trial of Bendamustine HCl Product Delivered via Low-Volume, Rapidly Infused Admixture

[News Story] WOODCLIFF LAKE, N.J.- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced positive results from a recently-conducted clinical trial of its bendamustine hydrochloride ("HCl") product, in which the dose was delivered in a 50mL admixture in ten minutes (the "rapidly infused product") versus a 500mL admixture in the 60-minute infusion required for Treanda(Registered) (bendamustine HCl).

In this study, Eagle's rapidly infused product was found to be bioequivalent to Treanda, which was the primary endpoint of the study.

[For more details click here.](#)

8-K other news

February 20: Eagle Pharmaceuticals: Entry into a Material Definitive Agreement

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_827871_000110465915012666_0001104659-15-012666.txt

Source: 8-K United States Securities and Exchange Commission

February 17: Eagle Pharmaceuticals: Results of Operations and Financial Condition

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_827871_000082787115000011_0000827871-15-000011.txt

Source: 8-K United States Securities and Exchange Commission

February 17: Eagle Pharmaceuticals: Other Events

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_827871_000110465915010852_0001104659-15-010852.txt

Source: 8-K United States Securities and Exchange Commission

January 20: Eagle Pharmaceuticals: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_827871_000082787115000004_0000827871-15-000004.txt

Source: 8-K United States Securities and Exchange Commission

January 12: Eagle Pharmaceuticals: Other Events

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_827871_000110465915001760_0001104659-15-001760.txt

Source: 8-K United States Securities and Exchange Commission

December 17: Eagle Pharmaceuticals: Results of Operations and Financial Condition

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_827871_000110465914087210_0001104659-14-087210.txt

Source: 8-K United States Securities and Exchange Commission

November 19: Eagle Pharmaceuticals: Other Events

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_827871_000110465914082026_0001104659-14-082026.txt

Source: 8-K United States Securities and Exchange Commission

September 26: Eagle Pharmaceuticals: Other Events

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_827871_000110465914068471_0001104659-14-068471.txt

Source: 8-K United States Securities and Exchange Commission

June 05: Eagle Pharmaceuticals: Other Events

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_827871_000110465914044133_0001104659-14-044133.txt

Source: 8-K United States Securities and Exchange Commission

Issued Capital

Based on 14,032,167 issued equity shares the market capitalisation is US\$472.3 million. It is NASDAQ's 68th largest Medical company by assets.


The top fifteen shareholders hold 11.6% of the issued capital leaving a float of 88.4%.

Company Overview (continued)

Top 10 Shareholders

Name of Shareholder	No. of Shares	% Held
Jennison Associates Llc	689,394	4.91
Cormorant Asset Management Llc	400,000	2.85
Wall Street Associates	200,000	1.43
Cam Group Holding A/S	140,000	1
Farallon Capital Management Llc	100,000	0.71
D. E. Shaw & Co. Inc.	35,374	0.25
Geode Capital Management Llc	29,895	0.21
Bridgeway Capital Management Inc	16,968	0.12
Banque Pictet & Cie Sa	13,209	0.09
Morgan Stanley	5,183	0.04
Total	1,630,023	11.62

Top 15 Institutional Holdings



Board and Management

Scott Tarriff CEO & President & Director

Mr. Tarriff is the founder and has served as our President and Chief Executive Officer and as a member of our board of directors since our inception in January 2007. Prior to joining Eagle, Mr. Tarriff held various executive positions at Par Pharmaceutical Companies, Inc., a publicly traded developer, manufacturer and marketer of specialty pharmaceuticals, including as president and chief executive officer from September 2003 to September 2006, after joining Par in 1998. Mr. Tarriff also served on Par's board of directors from 2002 to September 2006. Prior to that, Mr. Tarriff held various positions with Bristol-Meyers Squibb, a publicly-traded biopharmaceutical company, including senior director-marketing. Mr. Tarriff has served as a director of Synthetic Biologics, Inc., a publicly traded biotechnology company, since February 2012 and previously served on the board of directors of Clinical Data, Inc., a publicly-traded pharmaceutical company, from September 2009 to April 2011 when Clinical Data was acquired by Forest Laboratories, Inc. Mr. Tarriff holds a B.S. in marketing from Pennsylvania State University and an M.B.A. from Rider College. The board of directors believes that Mr. Tarriff's extensive knowledge of our business, his management experience in the pharmaceutical industry, as well as his operational expertise, qualifies him to serve on our board of directors and as our President and Chief Executive Officer.

David E. Riggs CFO

David E. Riggs has served as our Chief Financial Officer since November 2013. From May 2010 until October 2013 Mr. Riggs served as a healthcare consultant to biotechnology and pharmaceutical companies. From March 2006 until May 2010 Mr. Riggs was Chief Financial Officer of Ferring Pharmaceuticals, Inc. a research-driven biopharmaceutical company devoted to isolating, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and osteoarthritis. From January 2003 until September 2005, Mr. Riggs held various positions at eXegenics Inc. (now OPCO Health Inc.) finally as Chief Executive Officer. From March 2000 until December 2001 Mr. Riggs was Senior Vice President and CFO of Axys Pharmaceuticals, Inc. (acquired by Celera Genomics Inc.) a biopharmaceutical company focused on discovery, design, and development of therapeutic small molecules for large worldwide medical markets. From February 1992 until February 2000 Mr. Riggs held various positions at Unimed Pharmaceuticals, Inc., a company focused on developing and commercializing products in HIV, oncology and Urology specialty markets. Prior to that, Mr. Riggs held various positions at Fujisawa Pharmaceuticals, Inc. (acquired by Astellas Pharma, Inc.), including Treasurer and Director of Financial Planning and Analysis. Mr. Riggs holds a B.S. in Accounting from the University of Illinois and M.B.A. from DePaul University.

Michael Graves Director

Michael Graves has served as a member of our board of directors since November 2013. In January 2012 Mr. Graves joined the board of directors of RiboCor, Inc. and in December 2011, Mr. Graves was appointed chairman of the board of directors of Nanocopoeia, Inc., both private pharmaceutical companies. From May 2007 to July 2011, Mr. Graves served as the chief executive officer and president of Paddock Laboratories, Inc., a pharmaceutical company engaged in the manufacture, distribution and marketing of bioequivalent generic pharmaceuticals. From September 2005 to November 2006, Mr. Graves served as president of the generic products division at Par Pharmaceutical Companies, Inc., a publicly-traded developer, manufacturer and marketer of specialty pharmaceuticals. While at Par, Mr. Graves oversaw the strategy development of Par's generic pharmaceutical business. Beginning in 1998, Mr. Graves served as director of marketing and sales operations of Par, and in 2004, Mr. Graves was promoted to senior vice president of corporate development and strategic planning. Mr. Graves served in this position until his promotion to president of the generic products division in September 2005. Mr. Graves holds a B.S. from State University College of New York at Buffalo. The board of directors believes that Mr. Graves' extensive experience in marketing, sales, business development and operations qualifies him to serve on our board of directors.

Board and Management (continued)

Alain Schreiber Director

Alain Schreiber, M.D. has served as a member of our board of directors since September 2012. Since 2000, Dr. Schreiber has served as a general partner of ProQuest Investments. From 1992 to 2000, Dr. Schreiber served as president, chief executive officer and a director of Vical, Inc., a publicly-traded biopharmaceutical company. Prior to that, Dr. Schreiber held various management positions with Rhône-Poulenc Rorer Inc., a French chemical and pharmaceutical company that is now Sanofi-Aventis, including senior vice president of discovery research. Dr. Schreiber served on the board of directors of Cadence Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, from July 2004 to June 2007. Dr. Schreiber also served on the board of directors of Optimer Pharmaceuticals Inc., a publicly-traded biopharmaceutical company, from May 2001 to May 2010. Dr. Schreiber also currently serves on the board of directors of numerous private pharmaceutical companies. Dr. Schreiber holds a B.S. in chemistry and an M.D. from the Free University in Brussels, Belgium. Subsequently, he was a postdoctoral fellow at the Weizmann Institute of Science in Israel. Our board believes that Dr. Schreiber's extensive industry experience and a depth of drug development expertise, as well as his service on the board of directors of public and private companies, qualifies him to serve on our board of directors.

Sander Flaum Director

Sander Flaum has served as a member of our board of directors since February 2008. Since January 2005, Mr. Flaum has served as a principal of Flaum Navigators, a healthcare consultancy firm that he founded. Mr. Flaum has also served as the chief executive officer of Flaum Partners, Inc., a healthcare consultancy firm he founded, since August 2004. From 1991 to 2002, Mr. Flaum served as chief executive officer of Robert A. Becker EURO/RSCG, a predecessor to Euro RSCG Life. Prior to that, Mr. Flaum held various positions during an 18-year career at Lederle Laboratories, a private vaccine manufacturer that is now Wyeth Pharmaceuticals, including as marketing director of prescription products, vaccines and generics. Mr. Flaum is a member of the Euro RSCG Healthcare Global Network, and he has served as its co-chairman since 1998. Mr. Flaum also serves on the board of directors of The Fisher College of Business at The Ohio State University, The James Cancer Center at the OSU Medical Center and the Fordham Graduate School of Business. Mr. Flaum is an adjunct professor of leadership at the Fordham University Graduate School of Business, where he chairs the Fordham Leadership Forum. Mr. Flaum holds a B.A. from The Ohio State University and an M.B.A. from Fairleigh Dickinson University. Our board of directors believes that Mr. Flaum's extensive experience in the pharmaceutical and biotech industries qualifies him to serve on our board of directors.

Board and Management (continued)

Jay Moorin Director

Jay Moorin has served as a member of our board of directors since March 2007. In October 2013, our board of directors elected Mr. Moorin chairman of the board. Since 1998, Mr. Moorin has served as a founding general partner of ProQuest Investments, a healthcare venture capital firm. From 1991 to 1998, Mr. Moorin served as president and chief executive officer of Magainin Pharmaceuticals Inc., a publicly-traded biopharmaceutical company that is now named Genaera Corp., and also served as chairman of its board of directors from 1996 to 1998. Previously, Mr. Moorin served as managing director of healthcare banking at Bear Stearns & Co. Inc. and vice president of marketing and business development at a division of the ER Squibb Pharmaceutical Company. Currently, Mr. Moorin serves on the board of directors of a private radiation therapy company, is an advisor to DPT Capital Management, LLC, an investment firm, and serves as a trustee of the Equinox Funds Trust. Mr. Moorin held the position of adjunct senior fellow of the Leonard Davis Institute of Health Economics at the University of Pennsylvania from 1997 to 2012. Previously, Mr. Moorin served on the board of directors of numerous public and private healthcare companies. Mr. Moorin holds a B.A. in economics from the University of Michigan. Our board of directors believes that Mr. Moorin's extensive senior management background and experience in the biotech, investment banking and pharmaceutical industries as well as his service on the board of directors of public and private companies qualifies him to serve on our board of directors.

Financial Results (Quarterly)

30 September, 2014

Quarterly Report: Eagle Pharmaceuticals (NASDAQ:EGRX) \$US9.1m loss

Quarter ended Sep 30, 2014

Highlights

- Loss of \$US9.1m
- EPS of -64.93 U.S. cents

Unfavourable Changes:

- EBITDA loss of \$US9.1m
- EBIT loss of \$US9.1m

Quarterly Report

Quarter on Quarter [sequential comparison]	Sep 30, 2014	Jun 30, 2014	Change
Description	\$US ('000)	\$US ('000)	(%)
Sales Revenue	2,811.0	16,288.2	Down 82.7
EBITDA	(9,101.0)	(10,162.2)	Reduced 10.4
EBIT	(9,101.0)	(10,162.2)	Reduced 10.4
Interest	3.0	6.2	Down 52.0
Pre Tax Profit/(Loss)	(9,104.0)	(10,168.5)	Reduced 10.5
Profit/(Loss) after Tax	(9,104.0)	(10,539.6)	Reduced 13.6
Cash and cash equivalents	22,722.0	49,790.9	Down 54.4
Net Assets	33,096.0	41,910.7	Down 21.0
Per Share figures	-	-	-
EPS	(64.9 U.S. cents)	(\$US1.2)	Reduced 47.2

BuySellSignals Financial Research provides equity research on over 48,000 companies listed in more than 90 countries and 120 markets across the world. BuySellSignals believes that every stock has a story to tell and that this story changes every day. To capture this story, BuySellSignals offers the latest pertinent and comprehensive information so that investors can make well-informed investment decisions.

BuySellSignals publishes equity research reports on each stock, sector and index daily to capture the latest market movements and sentiments. BuySellSignals eschews "hot tip" or headline investing in favour of high-quality, ultra-current, targeted technical and fundamental information including specific bullish and bearish signals for each stock. Insights that will guide you to the investments that are hard to find in today's hyperactive mainstream markets.

For further details on definitions and quotations from investing legends, [Click here](#)

Disclaimer: While this document is based on information sources which are considered reliable, it has been prepared without consideration of your specific investment objectives, financial situation or needs, so you should carry out your own analysis or seek professional investment advice before an investment decision is made. The document contains unbiased, independent equities data from BuySellSignals (AFS Licence 222756) and News Bites Pty Ltd, who provide round the clock data on every Australian stock and sector. Neither BuySellSignals nor News Bites are brokers, and neither have an executing, corporate advisory or investment banking function. BuySellSignals and News Bites Pty Ltd, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. The data is sourced from annual reports and company releases and may not be fully up to date. It should be used as a guide only.
